Shares of Immunome (IMNM), a biotechnology company specializing in targeted oncology therapies, have dropped more than 50% from their 52-week high of $30.96, recorded in March, to trade around $13.
Immunome's lead drug candidate, AL102, is currently in a Phase 3 portion, of the Phase II/III trial, for the treatment of desmoid tumors, a rare and debilitating type of soft tissue cancer, dubbed RINGSIDE Part B.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com